Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications

Frontiers in Immunology

Volumn 4, Issue SEP, 2013, Pages

  Van Braeckel Budimir, Natalija ^a   Haijema, Bert Jan ^a   Leenhouts, Kees ^a  

^a Mucosis BV   (Netherlands)

Author keywords

Carrier adjuvant; Influenza vaccines; Lactococcus lactis; Mucosal vaccine technology; Particles; RSV vaccines

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; INTERLEUKIN 12; MUCOSAL VACCINE; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM; BACTERIUM LIKE PARTICLE; CELL MATURATION; DENDRITIC CELL; DRUG SAFETY; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; INNATE IMMUNITY; LACTOCOCCUS LACTIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VIRUS TITRATION;

EID: 84886053974     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00282     Document Type: Article

References (64)

1. Moyle PM, Toth I. Modern subunit vaccines: development, components and research opportunities. ChemMedChem (2013) 8:360-76. doi:10.1002/cmdc.201200487.
2. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine (2010) 28(Suppl 3):C25-36. doi:10.1016/j.vaccine.2010.07.021.
3. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med (2005) 11:S63-8. doi:10.1038/nm1210.
4. Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb Perspect Biol (2010) 5(2):a000414. doi:10.1101/cshperspect.a000414.
5. Hancock IC. Bacterial cell surface carbohydrates: structure and assembly. Biochem Soc Trans (1997) 1:183-7.
6. Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen M, Steen A, et al. A novel surface display system for proteins on non-genetically modified Gram-positive bacteria. Appl Environ Microbiol (2006) 72:880-9. doi:10.1128/AEM.72.1.880-889.2006.
7. Buist G, Kok J, Leenhouts KJ, Dabrowska M, Venema G, Haandrikman AJ. Molecular cloning and nucleotide sequence of the gene encoding the major peptidoglycan hydrolase of Lactococcus lactis, a muramidase needed for cell separation. J Bacteriol (1995) 177:1554-63.
8. Roosmalen ML, van Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods (2006) 38:144-9. doi:10.1016/j.ymeth.2005.09.015.
9. Leenhouts K. Mimopath-based vaccine delivery. In: Singh M, editor. Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. New York: Springer (2013). p. 245-65.
10. Saluja V, Visser MR, Ter Veer W, Roosmalen ML, van Leenhouts K, Hinrichs WL, et al. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. Vaccine (2010) 28:7963-9. doi:10.1016/j.vaccine.2010.09.066.
11. Saluja V, Amorij JP, Roosmalen ML, van Leenhouts K, Huckriede A, Hinrichs WL, et al. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J (2010) 12:109-16. doi:10.1208/s12248-009-9168-2.
12. de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific responses through intranasal administration. Vaccine (2012) 6:4884-91. doi:10.1016/j.vaccine.2012.04.032.
13. Saluja V, Visser MR, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, et al. Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles. Eur J Pharm Biopharm (2010) 76:470-4. doi:10.1016/j.ejpb.2010.08.003.
14. Audouy SA, Selm S, van Roosmalen ML, van Post E, Kanninga R, Neef J, et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine (2007) 25:2497-506. doi:10.1016/j.vaccine.2006.09.026.
15. Ramirez K, Ditamo Y, Rodriguez L, Picking WL, Roosmalen ML, Leenhouts K, et al. Neonatal mucosal immunization with a non-living, non-enetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol (2010) 3:159-71. doi:10.1038/mi.2009.131.
16. Nganou-Makamdop K, van Roosmalen ML, Audouy SAL, van Gemert G, Leenhouts K, Hermsen CC, et al. Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice. Malar J (2012) 11:50. doi:10.1186/1475-2875-11-50.
17. Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and death in winter. Commun Dis Public Health (2000) 3:32-8.
18. Stohr K. Influenza-WHO cares. Lancet Infect Dis (2002) 2:517. doi:10.1016/S1473-3099(02)00366-3.
19. Lamb RA, Choppin PW. The gene structure and replication of influenza virus. Annu Rev Biochem (1983) 52:468-506. doi:10.1146/annurev.bi.52.070183.002343.
20. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. 4th ed. In: Knipe DM, Griffin DE, editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins (2001). p. 1487-531.
21. Artenstein AW. Influenza. In: Artenstein AW, editor. Vaccines: A Biography. New York: Springer (2010). p. 191-205.
22. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol (2004) 59:1-15. doi:10.1111/j.0300-9475.2004.01382.x.
23. Giudice EL, Campbell JD. Needle-free vaccination delivery. Adv Drug Deliv Rev (2006) 58:68-89. doi:10.1016/j.addr.2005.12.003.
24. Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol (2007) 20:441-52. doi:10.1089/vim.2007.0027.
25. de Haan L, Verweij WR, Holtrop M, Brands R, van Scharrenburg GJM, Palache AM, et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA-or IgG-mediated protective mucosal immunity. Vaccine (2001) 19:2898-907. doi:10.1016/S0264-410X(00)00556-9.
26. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine (2002) 20:2431-8. doi:10.1016/S0264-410X(02)00155-X.
27. Takada A, Matsushita S, Ninomiva A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 21:3212-8. doi:10.1016/S0264-410X(03)00234-2.
28. Asahi-Ozaki Y, Yoshikawa T, Jwakura Y, Suzuki Y, Tamura S, Kurata T, et al. Secretory IgA antibodies provide cross-portection against infection with different strains of influenza B virus. J Med Virol (2004) 74:328-35. doi:10.1002/jmv.20173.
29. Fujita Y, Taguchi H. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. Ther Deliv (2012) 3:749-60. doi:10.4155/tde.12.52.
30. Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood (2009) 113:3969-77. doi:10.1182/blood-2008-10-185421.
31. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology and immunology. Clin Microbiol Rev (2010) 23:74-98. doi:10.1128/CMR.00032-09.
32. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 13:371-84. doi:10.1128/CMR.13.3.371-384.2000.
33. Englund JA, Anderson LJ, Rhame FS. Mosocomial transmission of respiratory syncytial virus in immunocompromised. J Clin Microbiol (1991) 29:115-9.
34. Sun Z, Pan Y, Jiang S, Lu L. Respiratory syncytial virus entry inhibitors targeting F protein. Viruses (2013) 5:211-25. doi:10.3390/v5010211.
35. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev (2013) 4:CD006602. doi:10.1002/14651858.CD006602.pub4.
36. Kim H, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 89:422-34.
37. Tan L, Lemey P, Houspie L, Viveen MC, Jansen NJ, van Loon AM, et al. Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. PLoS ONE (2012) 7(12):e51439. doi:10.1371/journal.pone.0051439.
38. Rigter A, Widjaja I, Versantvoort H, Coenjaerts FEJ, van Roosmalen M, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS ONE (2013) 8(8):e71072. doi:10.1371/journal.pone.0071072.
39. Graham BS, Henderson GS, Tang YW, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol (1993) 151:2032-40.
40. Tang YW, Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest (1994) 94:1953-8. doi:10.1172/JCI117546.
41. Connors M, Giese NA, Kulkami AB, Firestone CY, Morse HC 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol (1994) 68:5321-5.
42. Iwasaki R, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science (2010) 327:291-5. doi:10.1126/science.1183021.
43. Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv Immunol (2011) 109:87-124. doi:10.1016/B978-0-12-387664-5.00003-0.
44. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol (2006) 311:17-58. doi:10.1007/3-540-32636-7_2.
45. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, et al. Inflamatory cytokines provide a third signal for activation of naïve CD4+ and CD8+ T cells. J Immunol (1999) 162:3256-62.
46. Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, Dumrese T, et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol (2002) 168:2880-6.
47. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell (2006) 124:783-801. doi:10.1016/j.cell.2006.02.015.
48. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med (2000) 343:338-44. doi:10.1056/NEJM200008033430506.
49. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defense. Clin Microbiol Rev (2009) 22:240-73. doi:10.1128/CMR.00046-08.
50. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 30:16-34. doi:10.3109/08830185.2010.529976.
51. Hajishengallis G, Lambris JD. Microbal manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol (2011) 11:187-200. doi:10.1038/nri2918.
52. Jin B, Sun T, Yu XH, Yang YX, Yeo AE. The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol (2012) 2012:1-32. doi:10.1155/2012/836485.
53. Krieg AM, Efler SM, Wittpot M, Al Adhami MJ, Davis HL. Induction of systemic Th1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CpG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother (2004) 27:460-71. doi:10.1097/00002371-200411000-00006.
54. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature (1999) 401:811-5. doi:10.1038/44605.
55. Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, et al. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor 2. Mol Biochem Parasitol (2003) 31:65-74. doi:10.1016/S0166-6851(03)00160-9.
56. Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci (2010) 67:4109-34. doi:10.1007/s00018-010-0464-x.
57. Kim M, Osborne NR, Zeng W, Donaghy H, McKinnon K, Jackson DC, et al. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes. J Immunol (2012) 188:4158-70. doi:10.4049/jimmunol.1103450.
58. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, et al. Neuron-released oligomeric a-synclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun (2013) 4:1562. doi:10.1038/ncomms2534.
59. Wu Q, Jiang D, Minor MN, Martin RJ, Chu HW. In vivo function of airway epithelial TLR2 in host defense against bacterial infection. Am J Physiol Lung Cell Mol Physiol (2011) 300:L579-86. doi:10.1152/ajplung.00336.2010.
60. Droemann D, Goldmann T, Branscheid D, Clark R, DalhoffK, Zabel P, et al. Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol (2003) 119:103-8.
61. Bakker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol (2003) 148:670-9. doi:10.1046/j.1365-2133.2003.05287.x.
62. Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol (2008) 83:692-701. doi:10.1189/jlb.0807586.
63. Imanishi T, Hara H, Suzuki S, Suzuki N, Akira S, Saito T. Cutting edge: TLR2 directly triggers Th1 effector function. J Immunol (2007) 178:6715-9.
64. Barr TA, Brown S, Mastroeni P, Gray D. B cell intrinsic MyD88 signals drive IFN-gamma production from T cells and control switch to IgG2c. J Immunol (2009) 183:1005-12. doi:10.4049/jimmunol.0803706.